Zenocutuzumab for Pancreatic Cancer: Who May Benefit?

What Is Zenocutuzumab and How Does It Treat Pancreatic Cancer?

Zenocutuzumab-zbco, marketed as Bizengri, binds to the HER2 and HER3 receptors on cancer cells. In tumors with an NRG1 fusion, abnormal neuregulin-1 signaling can activate a HER2-HER3 complex and drive cell growth. Blocking this interaction targets the molecular cause of the cancer rather than treating every pancreatic tumor in the same way.

The FDA granted accelerated approval for adults with advanced, unresectable or metastatic NRG1 fusion-positive pancreatic adenocarcinoma whose disease progressed after prior systemic treatment. The indication is narrow because NRG1 fusions occur in only a small minority of pancreatic cancers. Zenocutuzumab should therefore be considered a precision treatment for a defined biomarker group, not a replacement for established therapy in most patients.

What Evidence Supported the FDA Approval?

The FDA evaluated zenocutuzumab through the multicenter eNRGy study and an early-access program. Among 30 evaluable patients with NRG1 fusion-positive pancreatic adenocarcinoma, the confirmed overall response rate was 40%, according to the FDA approval notice. Responses lasted from several months to beyond one year in some participants.

These findings are clinically meaningful for a heavily pretreated population with limited options, but they do not establish that the medicine helps every eligible patient or definitively extends survival. Accelerated approval permits earlier access based on a surrogate outcome such as tumor response. Confirmatory research is required to verify the anticipated clinical benefit.

Who Should Be Tested for an NRG1 Fusion?

An NRG1 fusion cannot be identified from symptoms, routine imaging or standard blood tests. Detection generally requires molecular analysis of tumor tissue or, in selected circumstances, circulating tumor DNA. RNA-based sequencing can be particularly useful because some gene fusions may be missed by narrower testing methods.

Treatment decisions should account for the exact molecular result, previous therapies, general health and potential adverse effects. The prescribing information carries warnings concerning infusion-related reactions, embryo-fetal toxicity and left ventricular dysfunction. Common adverse reactions include diarrhea, musculoskeletal pain, fatigue, nausea, infusion-related reactions and rash, making monitoring and supportive care important throughout treatment.